Resource Library

This resource library includes tools and resources such as reports, white papers, news, patient information and downloadable materials related to the biosimilars, specific to multiple sclerosis (MS) and select anti-inflammatory/rheumatological biosimilars. Additionally, it includes key documents needed for your practice such as Medication Use Evaluation (MUE), P&T Committee articles, and checklists to help onboard new and emerging biosimilar products. Simply by clicking on the areas you wish to explore and access these valuable tools and resources.

18 Results

Resource Library

Resource type

Topic

Search for keywords in resource title

Engaging the Experts – A New Landscape: Biosimilars in Multiple Sclerosis

Health economics of disease-modifying therapy for multiple sclerosis in the United States

A place for biosimilars in the changing multiple sclerosis treatment

Multiple Sclerosis Biosimilars Landscape

Approved Risk Evaluation and Mitigation Strategies (REMS)

Natalizumab REMS Strategy

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?

Best Practices in Multiple Sclerosis Therapies

Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial

Efficacy and safety of proposed natalizumab biosimilar PB006 versus Tysabri® in patients with relapsing remitting multiple sclerosis: Primary data from the Phase III Antelope study (P6-4.003)

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations

Guidelines for Approval of DMT Biosimilars, Use In Europe Drafted

Biosimilar to Tysabri for Relapsing-Remitting MS Is On Its Way

Eye on Pharma: Natalizumab Injunction; Oral Ustekinumab Development; New Study for Secukinumab Biosimilar

Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA

Sandoz Submits 351(k) Application for Biosimilar Natalizumab to Treat MS